Isoprostanes and neuroprostanes as biomarkers of oxidative stress in neurodegenerative diseases

Oxidative Medicine and Cellular Longevity

Volumn 2014, Issue , 2014, Pages

  Miller, Elzbieta ^a,b   Morel, Agnieszka ^c   Saso, Luciano ^d   Saluk, Joanna ^c,e  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Rehabilitation Ward   (Poland)

^c UNIVERSITY OF LODZ   (Poland)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN; CEREBROSPINAL FLUID; FREE RADICALS; OXIDATIVE STRESS;

ALZHEIMER'S DISEASE; ANTI OXIDATIVE ACTIVITY; CENTRAL NERVOUS SYSTEMS; CREUTZFELDT-JAKOB DISEASE; HUNTINGTON'S DISEASE; LIPID PEROXIDATION; NEURODEGENERATIVE DISORDERS; NEUROLOGICAL DISEASE;

NEURODEGENERATIVE DISEASES;

BIOLOGICAL MARKER; ISOPROSTANE DERIVATIVE; LIPID; NEUROPROSTANE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; HUMAN; HUNTINGTON CHOREA; LIPID PEROXIDATION; MULTIPLE SCLEROSIS; NONHUMAN; OXIDATIVE STRESS; REVIEW; METABOLISM; PATHOLOGY;

BIOLOGICAL MARKERS; HUMANS; ISOPROSTANES; NEURODEGENERATIVE DISEASES; NEUROPROSTANES; OXIDATIVE STRESS;

EID: 84901253645     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2014/572491     Document Type: Review

References (101)

1. Enciu A. M., Gherghiceanu M., Popescu B. O., Triggers and effectors of oxidative stress at blood-brain barrier level: relevance for brain ageing and neurodegeneration. Oxidative Medicine and Cellular Longevity 2013 2013 12 297512 10.1155/2013/297512
2. Niki E., Lipid peroxidation products as oxidative stress biomarkers. BioFactors 2008 34 2 171 180 2-s2.0-69449108348 10.1002/biof.5520340208
3. Santos R., Almodovar C. R., Bulteau A. L., Gomes C. M., Neurodegeneration, neurogenesis, and oxidative stress. Oxidative Medicine and Cellular Longevity 2013 2013 2 730581 10.1155/2013/730581
4. Cappellano G., Carecchio M., Fleetwood T., Magistrelli L., Cantello R., Dianzani U., Comi C., Immunity and inflammation in neurodegenerative diseases. American Journal of Neurodegenerative Disease 2013 2 2 89 107
5. Almer G., Teismann P., Stevic Z., Halaschek-Wiener J., Deecke L., Kostic V., Przedborski S., Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients. Neurology 2002 58 8 1277 1279 2-s2.0-0037161253 (Pubitemid 34411875)
6. Farooqui T., Farooqui A. A., Lipid-mediated oxidative stress and inflammation in the pathogenesis of Parkinson's disease. Parkinson's Disease 2011 2011 9 2-s2.0-79953272320 10.4061/2011/247467 247467
7. Guest J., Grant R., Mori T. A., Croft K. D., Changes in oxidative damage, inflammation and [NAD(H)] with age in cerebrospinal fluid. PLoS ONE 2014 9 1 e85335 10.1371/journal.pone.0085335
8. Roberts L. J. II, Milne G. L., Isoprostanes. Journal of Lipid Research 2009 50 S219 S223 2-s2.0-66349102251 10.1194/jlr.R800037-JLR200
9. 2-isoprostane levels indicating oxidative stress in healthy siblings of multiple sclerosis patients. Neuroscience Letters 2007 414 3 233 236 2-s2.0-33847185147 10.1016/j.neulet.2006.12.044
10. 2-isoprostane in human and experimental transmissible spongiform encephalopathies. Journal of Neuropathology and Experimental Neurology 2000 59 10 866 871 2-s2.0-0033782842
11. 4-neuroprostanes are not increased in Alzheimer's disease. Annals of Neurology 2002 52 2 175 179 2-s2.0-0035984342 10.1002/ana.10272 (Pubitemid 34810597)
12. Yao Y., Zhukareva V., Sung S., Clark C. M., Rokach J., Lee V. M. Y., Trojanowski J. Q., Praticò D., Enhanced brain levels of 8,12-iso-iPF2 α -VI differentiate AD from frontotemporal dementia. Neurology 2003 61 4 475 478 2-s2.0-0042932786 (Pubitemid 37025363)
13. 2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB Journal 1998 12 15 1777 1783 2-s2.0-0032238783 (Pubitemid 28553673)
14. Browne S. E., Beal M. F., Oxidative damage in Huntington's disease pathogenesis. Antioxidants and Redox Signaling 2006 8 11-12 2061 2073 2-s2.0-33947675275 (Pubitemid 46489631)
15. Kralovicova S., Fontaine S. N., Alderton A., Alderman J., Ragnarsdottir K. V., Collins S. J., Brown D. R., The effects of prion protein expression on metal metabolism. Molecular and Cellular Neuroscience 2009 41 2 135 147 2-s2.0-67349103914 10.1016/j.mcn.2009.02.002
16. Wong B. S., Pan T., Liu T., Li R., Petersen R. B., Jones I. M., Gambetti P., Brown D. R., Sy M. S., Prion disease: a loss of antioxidant function? Biochemical and Biophysical Research Communications 2000 275 2 249 252 2-s2.0-0034726713 10.1006/bbrc.2000.3158
17. 2 in variant Creutzfeldt-Jakob disease. Neurology 2002 58 1 127 129 2-s2.0-0037039260 (Pubitemid 34041950)
18. Arlt S., Kontush A., Zerr I., Buhmann C., Jacobi C., Schröter A., Poser S., Beisiegel U., Increased lipid peroxidation in cerebrospinal fluid and plasma from patients with creutzfeldt-jakob disease. Neurobiology of Disease 2002 10 2 150 156 2-s2.0-0036070563 10.1006/nbdi.2002.0496 (Pubitemid 34775468)
19. Mitsumoto H., Santella R., Liu X., Bogdanov M., Zipprich J., Wu H. C., Mahata J., Kilty M., Bednarz K., Bell D., Gordon P. H., Hornig M., Mehrazin M., Naini A., Flint Beal M., Factor-Litvak P., Oxidative stress biomarkers in sporadic ALS. Amyotrophic Lateral Sclerosis 2008 9 3 177 183 2-s2.0-47249114425 10.1080/17482960801933942 (Pubitemid 351983180)
20. Zhang R., Zhang Q., Niu J., Lu K., Xie B., Cui D., Xu S., Screening of microRNAs associated with Alzheimer's disease using oxidative stress cell model and different strains of senescence accelerated mice. Journal of the Neurological Sciences 2014 338 57 64
21. Jacob K. D., Noren N., Hooten N., Trzeciak A. R., Evans M. K., Markers of oxidant stress that are clinically relevant in aging and age-related disease. Mech Ageing 2013 134 139 157
22. Farooqui A. A., Horrocks L. A., Farooqui T., Interactions between neural membrane glycerophospholipid and sphingolipid mediators: a recipe for neural cell survival or suicide. Journal of Neuroscience Research 2007 85 9 1834 1850 2-s2.0-34447300221 10.1002/jnr.21268 (Pubitemid 47051473)
23. Gonsette R. E., Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. Journal of the Neurological Sciences 2008 274 1-2 48 53 2-s2.0-53049093018 10.1016/j.jns.2008.06.029
24. Halliwell B., Lee C. Y. J., Using isoprostanes as biomarkers of oxidative stress: some rarely considered issues. Antioxidants and Redox Signaling 2010 13 2 145 156 2-s2.0-77953313356 10.1089/ars.2009.2934
25. Barrera G., Oxidative stress and lipid peroxidation products in cancer progression and therapy. ISRN Oncology 2012 2012 21 137289 10.5402/2012/137289
26. Dotan Y., Lichtenberg D., Pinchuk I., Lipid peroxidation cannot be used as a universal criterion of oxidative stress. Progress in Lipid Research 2004 43 3 200 227 2-s2.0-1542315587 10.1016/j.plipres.2003.10.001 (Pubitemid 38299193)
27. Milne G. L., Yin H., Hardy K. D., Davies S. S., Roberts L. J., Isoprostane generation and function. Chemical Reviews 2011 111 10 5973 5996 2-s2.0-80054080478 10.1021/cr200160h
28. Roberts L. J. II, Morrow J. D., Products of the isoprostane pathway: unique bioactive compounds and markers of lipid peroxidation. Cellular and Molecular Life Sciences 2002 59 5 808 820 2-s2.0-0036286490 10.1007/s00018-002- 8469-8 (Pubitemid 34628242)
29. 2-isoprostanes) in vivo 1. Journal of Lipid Research 2011 52 1 113 124 2-s2.0-78650919059 10.1194/jlr.M010264
30. Murphy R. C., Fahy E., Isoprostane nomenclature: more suggestions. Prostaglandins Leukotrienes and Essential Fatty Acids 2010 82 2-3 69 70 2-s2.0-77951646240 10.1016/j.plefa.2010.01.001
31. Harris S. G., Padilla J., Koumas L., Ray D., Phipps R. P., Prostaglandins as modulators of immunity. Trends in Immunology 2002 23 3 144 150 2-s2.0-0036499224 10.1016/S1471-4906(01)02154-8 (Pubitemid 34178297)
32. Reich E. E., Markesbery W. R., Roberts L. J. II, Swift L. L., Morrow J. D., Montine T. J., Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. American Journal of Pathology 2001 158 1 293 297 2-s2.0-0035144956 (Pubitemid 32096495)
33. Streck E. L., Czapski G. A., Gonçalves da Silva C., Neurodegeneration, mitochondrial dysfunction, and oxidative stress. Oxidative Medicine and Cellular Longevity 2013 2013 2 826046 10.1155/2013/826046
34. Chen Y., Morrow J. D., Roberts L. J. II, Formation of reactive cyclopentenone compounds in vivo as products of the isoprostane pathway. Journal of Biological Chemistry 1999 274 16 10863 10868 2-s2.0-0033574541 10.1074/jbc.274.16.10863 (Pubitemid 29191068)
35. Chen Y., Zackert W. E., Roberts L. J. II, Morrow J. D., Evidence for the formation of a novel cyclopentenone isoprostane, 15-A(2t)-isoprostane (8-iso-prostaglandin A2) in vivo. Biochimica et Biophysica Acta: Molecular and Cell Biology of Lipids 1999 1436 3 550 556 2-s2.0-0033521691 10.1016/S0005-2760(98)00168-4 (Pubitemid 29242934)
36. O'Brien R. D., Fats and oils analysis. Fats and Oils: Formulating and Processing for Applications 2009 3rd Boca Raton, Fla, USA CRC Press 197 260
37. 2-dihomo- isoprostanes as potential early biomarkers of lipid oxidative damage in Rett syndrome. Journal of Lipid Research 2011 52 12 2287 2297 2-s2.0-81855217494 10.1194/jlr.P017798
38. Barden A. E., Corcoran T. B., Mas E., Durand T., Galano J. M., Roberts L. J., Paech M., Muchatuta N. A., Phillips M., Mori T. A., Is there a role for isofurans and neuroprostanes in pre-eclampsia and normal pregnancy? Antioxidants and Redox Signaling 2012 16 2 165 169 2-s2.0-81755161465 10.1089/ars.2011.4214
39. Brooks J. D., Milne G. L., Yin H., Sanchez S. C., Porter N. A., Morrow J. D., Formation of highly reactive cyclopentenone isoprostane compounds (A 3/J3-isoprostanes) in vivo from eicosapentaenoic acid. Journal of Biological Chemistry 2008 283 18 12043 12055 2-s2.0-45549090724 10.1074/jbc.M800122200
40. 2-isoprostanes are not just markers of oxidative stress. Free Radical Biology and Medicine 2008 44 3 247 256 2-s2.0-38149020624 10.1016/j.freeradbiomed.2007.10.004
41. Zaja-Milatovic S., Gupta R. C., Aschner M., Milatovic D., Protection of DFP-induced oxidative damage and neurodegeneration by antioxidants and NMDA receptor antagonist. Toxicology and Applied Pharmacology 2009 240 2 124 131 2-s2.0-70349251175 10.1016/j.taap.2009.07.006
42. Milatovic D., Montine T. J., Aschner M., Measurement of isoprostanes as markers of oxidative stress. Methods in Molecular Biology 2011 758 195 204 2-s2.0-80052918467 10.1007/978-1-61779-170-3-13
43. 'Amico E. D., Factor-Litvak P., Santella R. M., Mitsumoto H., Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radical Biology & Medicine 2013 65 509 527 10.1016/j.freeradbiomed.2013.06. 029
44. Wong-Ekkabut J., Xu Z., Triampo W., Tang I. M., Tieleman D. P., Monticelli L., Effect of lipid peroxidation on the properties of lipid bilayers: a molecular dynamics study. Biophysical Journal 2007 93 12 4225 4236 2-s2.0-37349055140 10.1529/biophysj.107.112565 (Pubitemid 350294470)
45. Yehuda S., Rabinovitz S., Carasso R. L., Mostofsky D. I., The role of polyunsaturated fatty acids in restoring the aging neuronal membrane. Neurobiology of Aging 2002 23 5 843 853 2-s2.0-0036752552 10.1016/S0197-4580(02) 00074-X (Pubitemid 35217710)
46. Montine T. J., Neely M. D., Quinn J. F., Beal M. F., Markesbery W. R., Roberts L. J. II, Morrow J. D., Lipid peroxidation in aging brain and Alzheimer's disease. Free Radical Biology and Medicine 2002 33 5 620 626 2-s2.0-0036710931 10.1016/S0891-5849(02)00807-9 (Pubitemid 35245834)
47. Miller E., Walczak A., Saluk J., Ponczek M. B., Majsterek I., Oxidative modification of patient's plasma proteins and its role in pathogenesis of multiple sclerosis. Clinical Biochemistry 2012 45 1-2 26 30 2-s2.0-84855301917 10.1016/j.clinbiochem.2011.09.021
48. Korade Z., Xu L., Mirnics K., Porter N. A., Lipid biomarkers of oxidative stress in a genetic mouse model of Smith-Lemli-Opitz syndrome. Journal of Inherited Metabolic Disease 2013 36 1 113 122 10.1007/s10545-012-9504-z
49. 2-isoprostanes and isofurans using gas chromatography-mass spectrometry. Free Radical Biology & Medicine 2013 59 36 44 10.1016/j.freeradbiomed.2012.09.030
50. 2-isoprostanes in newborns. Journal of Maternal-Fetal and Neonatal Medicine 2012 25 1 114 118 2-s2.0-84859398376 10.3109/14767058.2012.664856
51. Milne G. L., Yin H., Morrow J. D., Human biochemistry of the isoprostane pathway. Journal of Biological Chemistry 2008 283 23 15533 15537 2-s2.0-47049114843 10.1074/jbc.R700047200
52. Milne G. L., Yin H., Hardy K. D., Davies S. S., Roberts L. J., Isoprostane generation and function. Chemical Reviews 2011 111 10 5973 5996 2-s2.0-80054080478 10.1021/cr200160h
53. Bleich S., Kropp S., Degner D., Zerr I., Pilz J., Gleiter C. H., Otto M., Rüther E., Kretzschmar H. A., Wiltfang J., Kornhuber J., Poser S., Creutzfeldt-Jakob disease and oxidative stress. Acta Neurologica Scandinavica 2000 101 5 332 334 2-s2.0-0034098268 10.1034/j.1600-0404.2000.9s290A.x (Pubitemid 30249539)
54. 2-isoprostanes are elevated in Huntington's disease. Neurology 1999 52 5 1104 1105 2-s2.0-0033596751 (Pubitemid 29161638)
55. Miller E., Mrowicka M., Saluk-Juszczak J., Ireneusz M., The level of isoprostanes as a non-invasive marker for in vivo lipid peroxidation in secondary progressive multiple sclerosis. Neurochemical Research 2011 36 6 1012 1016 2-s2.0-79955696219 10.1007/s11064-011-0442-1
56. 2 in variant Creutzfeldt-Jakob disease. Neurology 2002 58 1 127 129 2-s2.0-0037039260 (Pubitemid 34041950)
57. Walsh D. T., Perry V. H., Minghetti L., Cyclooxygenase-2 is highly expressed in microglial-like cells in a murine model of prion disease. Glia 2000 29 392 396 (Pubitemid 30121429)
58. Consilvio C., Vincent A. M., Feldman E. L., Neuroinflammation, COX-2, and ALS-a dual role? Experimental Neurology 2004 187 1 1 10 2-s2.0-1842714301 10.1016/j.expneurol.2003.12.009 (Pubitemid 38470006)
59. Roberts L. J. II, Fessel J. P., Davies S. S., The biochemistry of the isoprostane, neuroprostane, and isofuran pathways of lipid peroxidation. Brain Pathology 2005 15 2 143 148 2-s2.0-17444403972 (Pubitemid 40546170)
60. Milatovic D., Aschner M., Measurement of isoprostanes as markers of oxidative stress in neuronal tissue. Current Protocols in Toxicology 2009 unit 12.14 1 12 2-s2.0-61749089180 10.1002/0471140856.tx1214s39
61. Melo A., Monteiro L., Lima R. M. F., de Oliveira D. M., de Cerqueira M. D., El-Bachá R. S., Oxidative stress in neurodegenerative diseases: mechanisms and therapeutic perspectives. Oxidative Medicine and Cellular Longevity 2011 2011 14 2-s2.0-84855584833 10.1155/2011/467180 467180
62. Ortiz G. G., Pacheco-Moisés F. P., Bitzer-Quintero O. K., Ramírez-Anguiano A. C., Flores-Alvarado L. J., Ramírez- Ramírez V., Macias-Islas M. A., Torres-Sánchez E. D., Immunology and oxidative stress in multiple sclerosis: clinical and basic approach. Journal of Cerebral Blood Flow & Metabolism 2014 34 34 42 10.1038/jcbfm.2013.161
63. Sultana R., Butterfield D. A., Role of oxidative stress in the progression of Alzheimer's disease. Journal of Alzheimer's Disease 2010 19 1 341 353 2-s2.0-75149118997 10.3233/JAD-2010-1222
64. Ayala-Peña S., Role of oxidative DNA damage in mitochondrial dysfunction and Huntington's disease pathogenesis. Free Radical Biology & Medicine 2013 62 102 110 10.1016/j.freeradbiomed.2013.04.017
65. Butterfield D. A., Bader Lange M. L., Sultana R., Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. Biochimica et Biophysica Acta: Molecular and Cell Biology of Lipids 2010 1801 8 924 929 2-s2.0-77953257870 10.1016/j.bbalip.2010.02.005
66. Greco A., Minghetti L., Levi G., Isoprostanes, novel markers of oxidative injury, help understanding the pathogenesis of neurodegenerative diseases. Neurochemical Research 2000 25 9-10 1357 1364 2-s2.0-0034302893
67. Miller E., Neurodegenerative diseases. Advances in Experimental Medicine and Biology 2012 724 228 238
68. Karussis D., The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. Journal of Autoimmunity 2014 48-49 134 142 10.1016/j.jaut.2014.01.022
69. Gandhi S., Abramov A. Y., Mechanism of oxidative stress in neurodegeneration. Oxidative Medicine and Cellular Longevity 2012 2012 11 428010 10.1155/2012/428010
70. Peterson L. K., Fujinami R. S., Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis. Journal of Neuroimmunology 2007 184 1-2 37 44 2-s2.0-33847781937 10.1016/j.jneuroim.2006.11.015 (Pubitemid 46389415)
71. Miller E., Mrowicka M., Malinowska K., Mrowicki J., Saluk-Juszczak J., Kdziora J., Effects of whole-body cryotherapy on a total antioxidative status and activities of antioxidative enzymes in blood of depressive multiple sclerosis patients. World Journal of Biological Psychiatry 2011 12 3 223 227 2-s2.0-79954445480 10.3109/15622975.2010.518626
72. Ljubisavljevic S., Stojanovic I., Pavlovic D., Milojkovic M., Sokolovic D., Stevanovic I., Petrovic A., Suppression of the lipid peroxidation process in the CNS reduces neurological expression of experimentally induced autoimmune encephalomyelitis. Folia Neuropathologica 2013 51 51 57
73. Greco A., Minghetti L., Isoprostanes as biomarkers and mediators of oxidative injury in infant and adult central nervous system diseases. Current Neurovascular Research 2004 1 4 341 354 2-s2.0-20744437198
74. Mondragón-Rodríguez S., Perry G., Zhu X., Boehm J., Amyloid beta and tau proteins as therapeutic targets for Alzheimer's disease treatment: rethinking the current strategy. International Journal of Alzheimer's Disease 2012 2012 7 2-s2.0-84859760030 10.1155/2012/630182 630182
75. Savelieff M. G., Lee S., Liu Y., Lim M. H., Untangling amyloid- β tau, and metals in Alzheimer's disease. ACS Chemical Biology 2013 8 856 865 10.1021/cb400080f
76. Ellis G., Fang E., Maheshwari M., Roltsch E., Holcomb L., Zimmer D., Martinez D., Murray I. V. J., Lipid oxidation and modification of amyloid- β (A β) in vitro and in vivo. Journal of Alzheimer's Disease 2010 22 2 593 607 2-s2.0-79952480344
77. Sultana R., Perluigi M., Butterfield A. D., Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain. Free Radical Biology & Medicine 2013 62 157 169 10.1016/j.freeradbiomed. 2012.09.027
78. Pritchard S. M., Dolan P. J., Vitkus A., Johnson G. V. W., The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics. Journal of Cellular and Molecular Medicine 2011 15 8 1621 1635 2-s2.0-79960325654 10.1111/j.1582-4934.2011.01273.x
79. Zhao Y., Zhao B., Oxidative stress and the pathogenesis of Alzheimer's disease. Oxidative Medicine and Cellular Longevity 2013 2013 10 316523 10.1155/2013/316523
80. 4-neuroprostanes) derived from docosahexaenoic acid in vivo in humans by a stable isotope dilution mass spectrometric assay. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 2004 799 1 95 102 2-s2.0-0344628663 10.1016/j.jchromb.2003.10.036 (Pubitemid 37500867)
81. Long J., He P., Shen Y., Li R., New evidence of mitochondria dysfunction in the female Alzheimer's disease brain: deficiency of estrogen receptor- β Journal of Alzheimer's Disease 2012 30 545 558
82. Mancini A., Raimondo S., Persano M., Di Segni C., Cammarano M., Gadotti G., Silvestrini A., Pontecorvi A., Meucci E., Estrogens as antioxidant modulators in human fertility. International Journal of Endocrinology 2013 2013 6 607939 10.1155/2013/607939
83. 2- isoprostanes, in vivo markers of lipid peroxidation. Journal of Neurochemistry 1999 73 2 736 741 2-s2.0-0032797942 10.1046/j.1471-4159.1999.0730736.x (Pubitemid 29339848)
84. Sánchez-López F., Tasset I., Agüera E., Feijóo M., Fernández-Bolaños R., Sánchez F. M., Ruiz M. C., Cruz A. H., Gascón F., Túnez I., Oxidative stress and inflammation biomarkers in the blood of patients with Huntington's disease. Neurological Research 2012 34 721 724 10.1179/1743132812Y.0000000073
85. Sorolla M. A., Reverter-Branchat G., Tamarit J., Ferrer I., Ros J., Cabiscol E., Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radical Biology and Medicine 2008 45 5 667 678 2-s2.0-48449091060 10.1016/j.freeradbiomed.2008.05.014
86. Browne S. E., Beal M. F., Oxidative damage in Huntington's disease pathogenesis. Antioxidants and Redox Signaling 2006 8 11-12 2061 2073 2-s2.0-33947675275 (Pubitemid 46489631)
87. Haun F., Nakamura T., Lipton S. A., Dysfunctional mitochondrial dynamics in the pathophysiology of neurodegenerative diseases. Journal of Cell Death 2013 6 27 35
88. Stack E. C., Matson W. R., Ferrante R. J., Evidence of oxidant damage in Huntington's disease: translational strategies using antioxidants. Annals of the New York Academy of Sciences 2008 1147 79 92 2-s2.0-57649171133 10.1196/annals.1427.008
89. Gan L., Johnson J. A., Oxidative damage and the Nrf2-ARE pathway in neurodegenerative diseases. Biochimica et Biophysica Acta 2013 10.1016/j.bbadis.2013.12.011
90. Carrizzo A., Di Pardo A., Maglione V., Damato A., Amico E., Formisano L., Vecchione C., Squitieri F., Nitric oxide dysregulation in platelets from patients with advanced huntington disease. PLoS ONE 2014 9 2 e89745 10.1371/journal.pone.0089745
91. Stoy N., Mackay G. M., Forrest C. M., Christofides J., Egerton M., Stone T. W., Darlington L. G., Tryptophan metabolism and oxidative stress in patients with Huntington's disease. Journal of Neurochemistry 2005 93 3 611 623 2-s2.0-18144386929 10.1111/j.1471-4159.2005.03070.x (Pubitemid 40617621)
92. Klepac N., Relja M., Klepac R., Hećimović S., Babić T., Trkulja V., Oxidative stress parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease gene carriers and healthy subjects: a cross-sectional study. Journal of Neurology 2007 254 12 1676 1683 2-s2.0-37749000434 10.1007/s00415-007-0611-y
93. Wong B. S., Liu T., Li R., Pan T., Petersen R. B., Smith M. A., Gambetti P., Perry G., Manson J. C., Brown D. R., Sy M. S., Increased levels of oxidative stress markers detected in the brains of mice devoid of prion protein. Journal of Neurochemistry 2001 76 2 565 572 2-s2.0-0035145614 10.1046/j.1471-4159.2001. 00028.x (Pubitemid 32097032)
94. Guentchev M., Voigtländer T., Haberler C., Groschup M. H., Budka H., Evidence for oxidative stress in experimental prion disease. Neurobiology of Disease 2000 7 4 270 273 2-s2.0-0033826082 10.1006/nbdi.2000.0290
95. Wong B. S., Brown D. R., Pan T., Whiteman M., Liu T., Bu X., Li R., Gambetti P., Olesik J., Rubenstein R., Sy M. S., Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities. Journal of Neurochemistry 2001 79 3 689 698 2-s2.0-0034764599 10.1046/j.1471-4159.2001.00625.x (Pubitemid 33029942)
96. Bate C., Rutherford S., Gravenor M., Reid S., Williams A., Cyclo-oxygenase inhibitors protect against prion-induced neurotoxicity in vitro. NeuroReport 2002 13 15 1933 1938 2-s2.0-0037191416 (Pubitemid 35398964)
97. Boillée S., Vande Velde C., Cleveland D., ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006 52 1 39 59 2-s2.0-33749056809 10.1016/j.neuron.2006.09.018 (Pubitemid 44466358)
98. Pradat P. F., Attarian S., Camdessanché J. P., Carluer L., Cintas P., Corcia P., Echaniz-Laguna A., Gonzalez-Bermejo J., Guy N., Nicolas G., Perez T., Soriani M. H., Vandenberghe N., Verschueren A., Research in amyotrophic lateral sclerosis: what is new in 2009? Revue Neurologique 2010 166 8-9 683 698 2-s2.0-77955984158 10.1016/j.neurol.2010.03.006
99. Mitsumoto H., Santella R., Liu X., Bogdanov M., Zipprich J., Wu H. C., Mahata J., Kilty M., Bednarz K., Bell D., Gordon P. H., Hornig M., Mehrazin M., Naini A., Flint Beal M., Factor-Litvak P., Oxidative stress biomarkers in sporadic ALS. Amyotrophic Lateral Sclerosis 2008 9 3 177 183 2-s2.0-47249114425 10.1080/17482960801933942 (Pubitemid 351983180)
100. Barber S. C., Shaw P. J., Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radical Biology and Medicine 2010 48 5 629 641 2-s2.0-75149155060 10.1016/j.freeradbiomed.2009.11.018
101. Almer G., Guegan C., Teismann P., Naini A., Rosoklija G., Hays A. P., Chen C., Przedborski S., Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Annals of Neurology 2001 49 2 176 185 (Pubitemid 32157993)